Navigation Links
Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
Date:5/22/2013

NEW YORK, May 22, 2013 /PRNewswire/ -- The Lupus Research Institute (LRI) today is hosting the first international conference devoted to advancing new treatments for lupus nephritis, a serious kidney complication of lupus affecting up to 60 percent of patients. The conference launched a new international alliance of researchers specializing in lupus nephritis – the Lupus Nephritis Trials Network (LNTN).

More than 50 of the world's top experts on lupus and the kidney came together to focus on two critical questions: 1) Which new medicines have the greatest potential to treat lupus nephritis; 2) How should these medications be tested in clinical trials?

LRI Partners with LNTN for New Lupus Treatments
The conference is a part of an ongoing partnership between the LNTN and the LRI.  LNTN unites over 100 academic investigators from around the world to conduct clinical trials in lupus nephritis and to simplify the process of testing new drugs by developing standardized clinical trial methods. The Network has already secured U.S. government and European Union funding for three trials of new approaches to the treatment of lupus nephritis.

"We are grateful to the Lupus Research Institute for being a founding supporter of LNTN and for sponsoring this meeting, a first in the field of lupus nephritis," noted Betty Diamond , MD, Center for Autoimmune and Musculoskeletal Diseases at The Feinstein Institute for Medical Research. "Concentrating on highly innovative approaches, the Network is addressing a pressing need for safer and more effective treatments."  

"The LRI and LNTN are natural allies in the fight against kidney damage caused by lupus," commented Margaret Dowd , President and CEO of the Lupus Research Institute. "This conference demonstrates how breakthrough discoveries the LRI funded in lupus nephritis are informing the development of new treatments and accelerating clinical trials."

Lupus nephritis is one of the most common and most serious complications of lupus potentially causing kidney failure if uncontrolled.  An estimated one-third to one-half of lupus patients develops lupus nephritis within the first six months to three years of their lupus diagnosis. There is no cure for lupus nephritis, and current treatments rely on anti-inflammatory and immunosuppressive drugs that carry the risk of serious side effects.  

About Lupus
Lupus is a chronic, complex and prevalent autoimmune disease that affects more than 1.5-million Americans. In lupus, the immune system, which is designed to protect against infection, creates antibodies that attack the body's own tissues and organs.

About the Lupus Research Institute
The Lupus Research Institute (LRI), the world's leading private supporter of innovative research, pioneers discovery and champions scientific creativity to find solutions to lupus. The LRI's advocacy arm is its National Patient Coalition, a powerful network of state and local lupus organizations in large urban centers of the country that unite to prevent, treat and cure lupus by advocating for lupus on Capitol Hill.


'/>"/>
SOURCE Lupus Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
2. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
3. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
9. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
10. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2019)... ... June 14, 2019 , ... Land O' Lakes ... the release of their new website designed to help patients obtain useful information, read ... Land O’ Lakes, Florida Chiropractor, Dr. Michael Craven is committed to helping ...
(Date:6/13/2019)... ... June 13, 2019 , ... Alliance Cost Containment, LLC ... in the healthcare space. The $5.8M in savings is in addition to $17.6M saved ... $23.4M. , With an acquisition in Q4 2019, the client increased their Fortune 500 ...
(Date:6/13/2019)... ... June 13, 2019 , ... Homecare Homebase ... the new Smart Scheduling product, part of the HCHB Intelligence Suite, at the ... uses complex algorithms to create highly efficient routing, mapping and scheduling for home ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... Clinical Ink , a global ... announce that Jonathan Andrus , chief business officer at Clinical Ink, has been ... Center for Health Policy on July 1, 2019, in Washington, D.C. The workshop, ...
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School ... Science in Health Informatics (MSHI ) degree program to address the growing need for ... program is part of a larger effort for SHRS to bring more graduate degrees ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving ... being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose ...
(Date:6/12/2019)... ... June 12, 2019 , ... NDA Partners Chairman ... more than 25 years of experience in quality systems development, quality systems management, ... devices, has joined NDA Partners as an Expert Consultant. Her experience includes quality ...
(Date:6/12/2019)... ... 2019 , ... Ovation Travel Group, one of the largest ... Chairman and CEO Paul Metselaar has received the Children’s Health Fund’s Founder’s Award, ... New York City’s Capitale as part of the Children’s Health Fund’s 2019 Annual ...
Breaking Medicine News(10 mins):